RxDoctor Payments Data

Morgan Powell

Family · Vancouver, WANPI 1790870129

Payments from drug & device makers

$1,858in general payments, 2019–2025

Across 72 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$328
  • AstraZeneca$295
  • Lilly USA, LLC$261
  • GSK$214
  • Amgen$142
  • AbbVie$134
  • plus $484 from 10 others

What the payments were for

  • Food & beverage$1,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,858 in reported general payments places this provider in the 85th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$25,942
Medicare patients
102
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$40,459
JardianceEmpagliflozin23$28,804
OzempicSemaglutide13$12,862
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,021
PaxlovidNirmatrelvir/Ritonavir19$1,363
Atorvastatin Calcium131$1,286
Losartan Potassium102$945
Olmesartan Medoxomil23$915
Amlodipine Besylate74$864
Levothyroxine Sodium77$819
Lisinopril103$741
Metformin Hcl68$565
Valsartan14$531
Omeprazole29$530
Sertraline Hcl37$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$78$41,82257 claims
Boehringer IngelheimJardiance$111$28,80423 claims
Novo NordiskOzempic$328$12,86213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,706 family providers in Washington.

Other family in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →